BRPI0815567A2 - Anticorpos híbridos antialfa v-integrina projetados - Google Patents

Anticorpos híbridos antialfa v-integrina projetados

Info

Publication number
BRPI0815567A2
BRPI0815567A2 BRPI0815567-4A2A BRPI0815567A BRPI0815567A2 BR PI0815567 A2 BRPI0815567 A2 BR PI0815567A2 BR PI0815567 A BRPI0815567 A BR PI0815567A BR PI0815567 A2 BRPI0815567 A2 BR PI0815567A2
Authority
BR
Brazil
Prior art keywords
antialfa
integrine
hybrid antibodies
antibodies designed
designed
Prior art date
Application number
BRPI0815567-4A2A
Other languages
English (en)
Inventor
Simon Goodman
Diane Hahn
Francesc Mitjans
Jaume Adan
Kin-Ming Lo
Original Assignee
Merck Patent Gessellschaft Mit Beschraenkter Haftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gessellschaft Mit Beschraenkter Haftung filed Critical Merck Patent Gessellschaft Mit Beschraenkter Haftung
Publication of BRPI0815567A2 publication Critical patent/BRPI0815567A2/pt
Publication of BRPI0815567B1 publication Critical patent/BRPI0815567B1/pt
Publication of BRPI0815567B8 publication Critical patent/BRPI0815567B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0815567A 2007-07-17 2008-07-17 anticorpos híbridos anti-alfa v-integrina projetados, proteína de fusão e composição farmacêutica BRPI0815567B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07013964 2007-07-17
EP07013964.7 2007-07-17
PCT/EP2008/005852 WO2009010290A2 (en) 2007-07-17 2008-07-17 Engineered anti-alpha v- integrin hybrid antibodies

Publications (3)

Publication Number Publication Date
BRPI0815567A2 true BRPI0815567A2 (pt) 2015-02-18
BRPI0815567B1 BRPI0815567B1 (pt) 2019-06-04
BRPI0815567B8 BRPI0815567B8 (pt) 2021-05-25

Family

ID=40029330

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815567A BRPI0815567B8 (pt) 2007-07-17 2008-07-17 anticorpos híbridos anti-alfa v-integrina projetados, proteína de fusão e composição farmacêutica

Country Status (20)

Country Link
US (1) US8562986B2 (pt)
EP (2) EP2167128B1 (pt)
JP (1) JP5341889B2 (pt)
KR (1) KR101559596B1 (pt)
CN (1) CN101687039B (pt)
AU (1) AU2008277907B2 (pt)
BR (1) BRPI0815567B8 (pt)
CA (1) CA2693863C (pt)
CY (1) CY1113493T1 (pt)
DK (1) DK2167128T3 (pt)
EA (1) EA019485B1 (pt)
ES (1) ES2395799T3 (pt)
HK (1) HK1143523A1 (pt)
HR (1) HRP20120949T1 (pt)
IL (1) IL203269A (pt)
PL (1) PL2167128T3 (pt)
PT (1) PT2167128E (pt)
SI (1) SI2167128T1 (pt)
WO (1) WO2009010290A2 (pt)
ZA (1) ZA201001124B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA020764B1 (ru) 2008-12-23 2015-01-30 Мерк Патент Гмбх Биомаркеры для ингибиторов с антиангиогенной активностью
CA2771441C (en) 2009-08-19 2016-10-11 Merck Patent Gmbh Antibodies for the detection of integrin complexes in ffpe material
SI2672994T1 (sl) * 2011-02-11 2018-09-28 Merck Patent Gmbh Protitelo proti alfa-v integrinu za zdravljenje raka prostate
AU2014318017B2 (en) * 2013-09-05 2020-02-06 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
MX2017003015A (es) 2014-09-17 2017-05-23 Merck Patent Gmbh Metodo para tratar canceres solidos y/o metastasis de los mismos, medicamentos para los mismos, y metodo para predecir el resultado clinico para tratar canceres solidos y/o metastasis de los mismos.
ES2897782T3 (es) 2014-09-17 2022-03-02 Merck Patent Gmbh Método de tratamiento de las enfermedades de la metástasis ósea, medicamentos para el tratamiento y método para predecir el resultado clínico del tratamiento de las enfermedades causadas por metástasis ósea
SI3221346T1 (sl) 2014-11-21 2020-11-30 Bristol-Myers Squibb Company Protitelesa vsebujoča modificirana težko konstantna območja
BR112017010110A2 (pt) 2014-11-21 2018-01-30 Bristol-Myers Squibb Company anticorpos contra cd73 e usos do mesmo
MX2018006269A (es) * 2015-11-23 2018-09-05 Merck Patent Gmbh Anticuerpo anti-alfa-v-integrina para el tratamiento de fibrosis y/o trastornos fibroticos.
US20190144547A1 (en) * 2015-11-23 2019-05-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
EP3510407A1 (en) 2016-09-08 2019-07-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating nephrotic syndrome
EP4252629A3 (en) 2016-12-07 2023-12-27 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
EP4233902A3 (en) 2016-12-14 2024-02-28 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
CN110382537B (zh) 2017-02-02 2023-07-25 默克专利有限公司 抗体结构域的优选配对
CN108948206B (zh) * 2017-05-23 2022-08-23 赵磊 一种抗egfr/pd-1双靶向抗体、其制备方法及用途
US11623963B2 (en) 2017-10-03 2023-04-11 Merck Patent Gmbh Cysteine engineered antigen-binding molecules
US11339221B2 (en) 2017-11-01 2022-05-24 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use
EP3810085A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
EP3867276A1 (en) 2018-10-19 2021-08-25 Merck Patent GmbH Abituzumab for the treatment of colorectal cancer
EP3883634A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
EP4309722A2 (en) 2019-12-13 2024-01-24 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN114366749B (zh) * 2020-10-15 2023-06-30 中国人民解放军海军军医大学 整合素抑制剂在制备治疗肾癌的药物中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2082160C (en) 1991-03-06 2003-05-06 Mary M. Bendig Humanised and chimeric monoclonal antibodies
DK0719859T3 (da) * 1994-12-20 2003-10-20 Merck Patent Gmbh Anti-alfa V-integrin monoklonalt antistof
JP3461945B2 (ja) 1994-12-26 2003-10-27 株式会社日本製鋼所 高低圧一体型タービンロータの製造方法
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
WO2000034317A2 (en) 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
EP1998266A3 (en) 2001-02-19 2009-02-11 Merck Patent GmbH Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity
KR20110140143A (ko) * 2002-11-26 2011-12-30 애보트 바이오테라퓨틱스 코포레이션 혈관형성을 조절하는 α5β1 인테그린에 대한 키메라성 및 인간화 항체
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
KR20060002667A (ko) 2004-07-03 2006-01-09 삼성전자주식회사 디스크 댐퍼와 디스크 프로텍터를 구비한 하드 디스크드라이브
CA2635623C (en) 2005-12-30 2015-02-17 Michael Super Anti-cd19 antibodies with reduced immunogenicity
US7669429B2 (en) 2006-01-19 2010-03-02 Bassler Sr G Scott Rapid food chiller

Also Published As

Publication number Publication date
CN101687039B (zh) 2014-04-16
BRPI0815567B8 (pt) 2021-05-25
WO2009010290A3 (en) 2009-04-09
EA019485B1 (ru) 2014-04-30
US20100254977A1 (en) 2010-10-07
US8562986B2 (en) 2013-10-22
CY1113493T1 (el) 2016-06-22
JP5341889B2 (ja) 2013-11-13
AU2008277907B2 (en) 2013-08-22
KR20100057010A (ko) 2010-05-28
CA2693863A1 (en) 2009-01-22
SI2167128T1 (sl) 2013-01-31
EP2167128A2 (en) 2010-03-31
HRP20120949T1 (en) 2012-12-31
DK2167128T3 (da) 2012-12-03
WO2009010290A2 (en) 2009-01-22
ES2395799T3 (es) 2013-02-15
PT2167128E (pt) 2013-01-24
JP2010533480A (ja) 2010-10-28
CN101687039A (zh) 2010-03-31
HK1143523A1 (en) 2011-01-07
PL2167128T3 (pl) 2013-03-29
EA201070150A1 (ru) 2010-08-30
ZA201001124B (en) 2010-11-24
CA2693863C (en) 2017-10-03
IL203269A (en) 2014-11-30
KR101559596B1 (ko) 2015-10-12
EP2526967A1 (en) 2012-11-28
AU2008277907A1 (en) 2009-01-22
EP2167128B1 (en) 2012-10-24
BRPI0815567B1 (pt) 2019-06-04

Similar Documents

Publication Publication Date Title
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0815567A2 (pt) Anticorpos híbridos antialfa v-integrina projetados
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
BRPI0907237A2 (pt) Anticorpo anti-cldn6
BRPI0807895A2 (pt) Veículo híbrido
DE602008000562D1 (de) Fahrzeugrad
BRPI0811014A2 (pt) Veículo
BRPI0917148A2 (pt) anticorpos anti-cd5
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
DE602008001297D1 (de) Fahrzeugrad
BRPI0817427A2 (pt) Anticorpo anti-bst2
DE112008002581A5 (de) Antriebsstrang
BRPI0909633A2 (pt) anticorpos anti-tyrp1
DK2132234T3 (da) Acceleratoropløsning
DE112007003038A5 (de) Antriebsstrang
DE602008000034D1 (de) Rollerartiges Fahrzeug
BRPI0912769A2 (pt) anticorpos anti-pirb
DE602008006114D1 (de) Fahrzeugrad
BRPI0817451A2 (pt) Veículo pequeno
DE602008005512D1 (de) Fahrzeug
DE112007003032A5 (de) Antriebsstrang
DE502008002253D1 (de) Fahrzeug
DE602008004404D1 (de) Fahrzeug-Odometersystem
AT504969A3 (de) Fahrzeug
DE602008002478D1 (de) Hybridfahrzeug

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/07/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF